Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis
|
By LabMedica International staff writers Posted on 29 Apr 2016 |
Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.
Investigators at the Pennsylvania State College of Medicine (Hershey, USA) sought to determine whether miRNAs were differentially expressed in the blood of asthmatic patients compared with those in the blood of nonasthmatic patients with AR and nonallergic nonasthmatic subjects. Furthermore, they sought to establish whether miRNAs could be used to characterize or subtype asthmatic patients.
To these ends, they used real-time quantitative PCR to measure expression of plasma miRNAs in 35 asthmatic patients, 25 nonasthmatic patients with AR, and 19 nonallergic nonasthmatic subjects.
Results revealed 30 miRNAs that were differentially expressed among healthy, allergic, and asthmatic subjects. These miRNAs fit into five different expression pattern groups. Among asthmatic patients, miRNA expression profiles identified two subtypes that differed by high or low peripheral eosinophil levels. Circulating miR-125b, miR-16, miR-299-5p, miR-126, miR-206, and miR-133b levels were most predictive of allergic and asthmatic status.
"The role of miRNAs in asthma is not well understood, although it looks as though these molecules play very important roles in inflammation and in immune responses," said senior author Dr. Faoud Ishmael, associate professor of medicine, biochemistry, and molecular biology at Pennsylvania State College of Medicine.
"We found that there was a subset of these miRNAs that were unique to asthma, and that we could use them to predict if someone had it based on if they were high or low compared to the other two groups," said Dr. Ishmael. "There is a different molecular fingerprint if you have asthma compared to if you have allergic rhinitis or neither.
Eosinophils play very important roles in some kind of allergic reactions, and they might have implications for how people respond to some of the treatments that are already on the market for asthma. We think this may be useful technology to distinguish between some of these different sub-types so we know from the beginning when a treatment will not work for a patient."
The study was published in the March 26, 2016, online edition of The Journal of Allergy and Clinical Immunology.
Related Links:
Pennsylvania State College of Medicine
Latest Molecular Diagnostics News
- Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
- Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
- Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
- Patented Isothermal Amplification Chemistry Advances Decentralized Testing
- Direct-to-Patient Genetic Testing Identifies Hereditary Cancer Risk in Survivors
- Stool DNA Analysis Tracks Disease Activity in IBD
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Genomic Testing Program Improves Diagnosis of Congenital Hyperinsulinism
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
Channels
Clinical Chemistry
view channel
Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read moreAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








